Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06807112

The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma

Sponsor: Charles University, Czech Republic

View on ClinicalTrials.gov

Summary

The goal of this study is to assess the influence of pancreatic secretion stimulation by intravenously administered secretin on circulating tumor DNA in patients with pancreatic ductal adenocarcinoma. Additional aim of the study is to analyse a role of specific biomarkers in determining the prognosis of this disease. The main question o answer is: Does intravenous secretin administration potentiate the release of circulating tumor DNA in patients with pancreatis ductal adenocarcinoma? Additional question is: Is there a biomarker specific and sensitive enough to help to predict the prognosis and the at the time status of the disease? Participants scheduled for surgical treament due to pancreatic ductal adenocarcinoma will be included and stimulated with intravenously administered secretin, their peripheral blood samples will then be analyzed for ctDNA levels.

Official title: The Influence of Secretin Stimulated Pancreatic Secretion on Circulating Tumor DNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

39

Start Date

2025-02-09

Completion Date

2027-02-01

Last Updated

2025-02-04

Healthy Volunteers

No

Interventions

OTHER

Intravenously administered secretin

16 micrograms of liquid secretin will be one-time intravenously administered to patients with PDAC during the first hour of surgery. Four peripheral blood samples will then be collected. Plasmatic levels of ctDNA will be measured. Plasmatic levels of biomarkers such as mRNA, miRNA, siRNA, exoRNA, S100 proteins and amino acids, isolated from the same blood samples, will be measured and analyzed in correlation to tumor volumometry, survival rate etc. in specific intervals during follow-ups.

Locations (1)

Department of Surgery, Military University Hospital in Prague

Prague, Czechia